Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer

NCT05824481 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT05824481
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05824481 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer
Lead sponsor
Sun Yat-sen University
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 8, 2023
Completion date
June 30, 2026
Enrollment
32 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial adenocarcinoma, endometrial cancer